The MA17 trial showed that addition of letrozole after 5 years tamoxifen was effective in further reducing the risk of relapse in women with breast cancer. Recent data also indicate that the cost of breast cancer relapse is much higher than previously shown, which has important implications for the benefit of adjuvant treatment. Further, the cost-effectiveness of adjuvant treatment from a societal perspective and in the Nordic countries is so far not extensively assessed. The objective of this study was to assess cost-effectiveness of extending the adjuvant therapy in Sweden, from a societal perspective. METHODS: Consequences for a woman at the age of 62 years who have completed 5 years tamoxifen treatment were assessed, from a societal and health care perspective. Clinical data on risk of relapse and adverse events were based on the MA17 trial. Costs, health utilities and survival data were based on recent detailed Swedish data. A reduction in relapse risk was extrapolated into a survival benefit, by assuming a higher mortality for patients with relapse. RESULTS: The total societal cost for letrozole-and placebotreated patients were €7700 and €6300, respectively, a difference of €1500. The difference in life-years and QALYs were 0.23 and 0.18, respectively, leading to costs of €6500 per life-years gained and €8300 per QALY gained. The corresponding costeffectiveness ratios from a health care perspective were €10,500 per life-years gained and €13,400 per QALY gained. CONCLU-SIONS: The study indicates that the incremental cost per QALY gained for extended letrozole treatment in Sweden is low, and hence indicates that money spent of extending the adjuvant treatment with letrozole probably is money well spent in Sweden. More long-term data on the overall survival gain would be valuable to further validate the assumption used in the analysis. [DFS], relapse/new occurrence of colon carcinoma, and death) Markov model was used to explore the effects of adding one year of adjuvant treatment with bevacizumab to the existing adjuvant FOLFOX4 treatment regimen. Baseline DFS for FOLFOX4-treated patients was based on published data from the MOSAIC trial (André et al 2004). The relative risk reduction for bevacizumab was based on protocol assumptions for the ongoing phase III AVANT study. Outcomes included life-years, QALYs, direct costs, and incremental cost-effectiveness ratios (ICERs) expressed as costs per QALY or life-year gained. A life time horizon (40 Abstracts A471
Novartis Sweden, Täby, Sweden, 2 Akademiska Hospital, Uppsala, Sweden OBJECTIVES: The MA17 trial showed that addition of letrozole after 5 years tamoxifen was effective in further reducing the risk of relapse in women with breast cancer. Recent data also indicate that the cost of breast cancer relapse is much higher than previously shown, which has important implications for the benefit of adjuvant treatment. Further, the cost-effectiveness of adjuvant treatment from a societal perspective and in the Nordic countries is so far not extensively assessed. The objective of this study was to assess cost-effectiveness of extending the adjuvant therapy in Sweden, from a societal perspective. METHODS: Consequences for a woman at the age of 62 years who have completed 5 years tamoxifen treatment were assessed, from a societal and health care perspective. Clinical data on risk of relapse and adverse events were based on the MA17 trial. Costs, health utilities and survival data were based on recent detailed Swedish data. A reduction in relapse risk was extrapolated into a survival benefit, by assuming a higher mortality for patients with relapse. RESULTS: The total societal cost for letrozole-and placebotreated patients were €7700 and €6300, respectively, a difference of €1500. The difference in life-years and QALYs were 0.23 and 0.18, respectively, leading to costs of €6500 per life-years gained and €8300 per QALY gained. The corresponding costeffectiveness ratios from a health care perspective were €10,500 per life-years gained and €13,400 per QALY gained. CONCLU-SIONS: The study indicates that the incremental cost per QALY gained for extended letrozole treatment in Sweden is low, and hence indicates that money spent of extending the adjuvant treatment with letrozole probably is money well spent in Sweden. More long-term data on the overall survival gain would be valuable to further validate the assumption used in the analysis. , relapse/new occurrence of colon carcinoma, and death) Markov model was used to explore the effects of adding one year of adjuvant treatment with bevacizumab to the existing adjuvant FOLFOX4 treatment regimen. Baseline DFS for FOLFOX4-treated patients was based on published data from the MOSAIC trial (André et al 2004) . The relative risk reduction for bevacizumab was based on protocol assumptions for the ongoing phase III AVANT study. Outcomes included life-years, QALYs, direct costs, and incremental cost-effectiveness ratios (ICERs) expressed as costs per QALY or life-year gained. A life time horizon (40 Abstracts A471 years) was used; after 8 years, patients were assumed to only be at risk for death. Costs and outcomes were discounted at 3.5% per annum. Sensitivity analyses were performed to identify influential parameters in the model. RESULTS: Undiscounted mean life expectancy for patients treated with FOLFOX4 was estimated at 15.9 years. Assuming the addition of bevacizumab reduces the risk of relapse by 23% in the first 3 years after surgery, as described in the protocol, and by 10% in the following 5 years, mean survival was estimated to increase to 18.1 years (10.8 to 12.1 years when discounted). The discounted ICER was £19,939/life year gained. Sensitivity analysis showed that assumptions relating to the magnitude of the relapse risk reduction and the duration of risk reduction were the most critical determinants of the ICER. CONCLUSIONS: Addition of bevacizumab to FOLFOX4, the current standard regimen for patients with stage III colon carcinoma, is expected to improve clinical outcomes and to be a cost-effective treatment option from a UK perspective. The model assumes a hypothetical patient cohort similar to those of HERA study. The evaluation assumes both the health care payer and societal perspectives. Portuguese NHS resource use and costs were estimated from a consensus experts panel and published unit costs, respectively, including cancer therapy costs, adverse cardiovascular events treatment costs, disease diagnosis and management costs and indirect costs (time off of work). Outcomes were discounted at 3% per annum. One-way sensitivity analysis was performed on the discount rate, quality of life estimates and non-trastuzumab treatment costs. RESULTS: Treatment with trastuzumab was estimated to increase discounted life expectancy by 2.11 in years (14.95 vs 12,84) and quality-adjusted life expectancy by 2.01 QALYs compared to standard care. Direct and indirect costs were projected to be €61.839 and €19,759 with trastuzumab and €40,559 and €25.391 with standard of care. These results corresponded to ICERs of €10,067 and €10,595 assuming direct costs only and of €7789 and €7400 including indirect costs, per life year gained (LYG) and per QALY gained, respectively. CONCLUSIONS: The 1-year trastuzumab use as adjuvant therapy in HER-2 positive eBC patients improves survival and can be considered a cost effective therapy with a high degree of certainty in the Portuguese setting. To obtain a Dutch cost-effectiveness estimate of trastuzumab in early breast cancer, based on a previous UK model-based cost-effectiveness analysis. Trastuzumab is a humanized monoclonal antibody against the HER2-receptor extracellular domain. METHODS: Following the model transferability assessment, required adjustments were made. In a Markov cohort model, 1 year adjuvant trastuzumab therapy was compared to observation. Model outcomes are life years, quality-adjusted life years (QALYs), health care costs, and cost of productivity loss. The cycle length is one year, the time horizon is lifetime. UK prices were replaced by updated Dutch unit prices. Clinical input data originated from the HERA-trial; health utilities were obtained from literature. The impact of parameter uncertainty was assessed using age subgroup analyses, one-way sensitivity analyses and probabilistic sensitivity analysis. Subsequently, we conducted expected value of perfect information analyses. RESULTS: In The Netherlands, from a health care perspective the ICER for trastuzumab for a 55 year old patient was estimated at €19,463/QALY. From a societal perspective the ICER became €14,867. As expected, ICERs improve with younger age. Sensitivity analyses showed that the ICER was sensitive to the time horizon and the costs for the metastasic health state. CONCLUSIONS: Overall the Dutch costeffectiveness estimate of trastuzumab for early stage breast cancer can be well described and is well below the Dutch informal threshold of €80,000/QALY. For the base case analysis the probability that the ICER is acceptable for thresholds above €27.000/QALY is 1, indicating a probability of zero for a wrong decision. Hence, for thresholds above €27,000 the expected value of information is zero. This analysis provided an early cost-effectiveness indication of trastuzumab in the adjuvant setting in The Netherlands and has led to the provisional reimbursement. The transferability assessment is addressed in a separate abstract. Bevacizumab recently received a revised marketing authorisation for use in CRC that states "Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum". This means that bevacizumab can be used in combination with a wider choice of therapies than previously allowed. This revised indication was based on the NO16966 phase III trial, which evaluated the efficacy of bevacizumab in combination with capecitabine + oxaliplatin (XELOX). METHODS: A health state transition model was constructed to estimate patient survival, stratified between progression-free sur-
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